Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune & Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GPR183/EBI2 (Epstein-Barr Virus Induced 2) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | GPR183 Full-Length Lentivirus Premade Particles Codon-optimized ORF, HEK293T packaged. For stable cell line generation preserving native GPCR conformation. |
View GPR183 Products |
| Gene Delivery (ORF) | GPR183 Promise-ORF Clones Ready-to-transfect mammalian expression vectors. |
View EBI2 Products |
| Validator | GPR183 siRNA Set (3 pre-designed + control) For knockdown validation and specificity controls. |
View GPR183 Products |
| Benchmark Ab | Anti-GPR183 Reference Antibody (Research Grade) Recombinant monoclonal for assay development and positive control. |
View GPR183 Products |
| Related Target: S1PR1 | S1PR1 (Sphingosine-1-phosphate Receptor 1) Synergistic pathway in lymphocyte trafficking; comparator for selectivity assays. |
View S1PR1 Products |
| Related Target: CXCR5 | CXCR5 (CXCL13 Receptor) Co-regulator of B-cell follicular positioning; cross-talk analysis target. |
View CXCR5 Products |
| Related Target: NR1H3 | LXR-alpha (NR1H3) Oxysterol-binding nuclear receptor; critical for off-target liability screening. |
View NR1H3 Products |
| Related Target: CCR7 | CCR7 Co-regulator of dendritic and T cell migration; key node in immune cell trafficking networks. |
View CCR7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Conformation Preservation | Full-length ORF Lentivirus for stable cell lines; HEK293T expressed with native glycosylation pattern. |
| Oxysterol Ligand Handling (7α,25-OHC) | Cell-based functional assays (Calcium Flux, Chemotaxis) using intact membrane environment. |
| Cross-species Translation (Cyno/Mouse) | Human/Mouse/Cyno GPR183 ortholog ORF clones available with sequence verification (>99% accuracy). |
| Constitutive Activity & False Positives | Validated siRNA included for target-specificity confirmation; endogenous expression background control. |
| Off-target Liability (Oxysterol Receptors) | Homolog panel (LXR-alpha, ROR-gamma) for selectivity screening. |
Live GPR183/EBI2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (GPR183)
- ➤ View Active Clinical Trials (EBI2)
- ➤ Latest Resistance & Mechanism Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for GPR183/EBI2 therapeutics is transitioning from exploratory biology to clinical validation, following the discontinuation of first-generation antibody approaches (Roche RG7744) and the emergence of oral small-molecule antagonists. As Escient Pharmaceuticals advances EP262 through Phase 1/2 for autoimmune indications, the competitive landscape is consolidating around GPCR-functional selectivity and CNS-penetrant formulations for multiple sclerosis. The next wave of R&D focuses on combination strategies with S1P modulators and refined patient stratification based on oxysterol metabolic profiles. Notably, a somatic mutation (dbSNP rs1466524306) has been reported in an acute myeloid leukemia sample (UniProt VAR_054147), highlighting potential oncogenic implications that may drive future companion diagnostic needs.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | Escient Pharmaceuticals, Roche (legacy) | Lupus, MS, Psoriasis, IBD | Calcium Flux & Chemotaxis Assays (Need full-length GPR183 stable cell lines) |
| Monoclonal Antibody | Genentech (discontinued), Academic consortia | Rheumatoid Arthritis | Receptor Internalization & Occupancy (Need high-expression lentivirus systems) |
| Gene Therapy / RNAi | Academic / Spin-offs | Asthma, Inflammation | Knockdown Validation (Need validated siRNA and lentivirus) |
| Combination Therapy | Emerging biotech | Autoimmune (S1P+GPR183) | Dual-target cell lines; Cross-reactivity panels (S1PR1/GPR183 co-expression) |